Not applicableStudy completedNCT03764631
What this trial is testing
Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration
Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 1,502